ES486007A1 - Un procedimiento de preparacion de un derivado de espiro- policicloimidazolidindiona - Google Patents

Un procedimiento de preparacion de un derivado de espiro- policicloimidazolidindiona

Info

Publication number
ES486007A1
ES486007A1 ES486007A ES486007A ES486007A1 ES 486007 A1 ES486007 A1 ES 486007A1 ES 486007 A ES486007 A ES 486007A ES 486007 A ES486007 A ES 486007A ES 486007 A1 ES486007 A1 ES 486007A1
Authority
ES
Spain
Prior art keywords
dihydro
spiro
derivatives
imidazolidine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES486007A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES486007A1 publication Critical patent/ES486007A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Nuevos derivados de espiro-policicloimidazolididiona útiles como inhibidores de la aldosa-reductasa y como agentes terapéuticas para el tratamiento de las complicaciones diabelticas crónicas. Entre estos derivados se encuentran la 2'', 3''-dihidro-espiro (imidazolin-4,4''-(4''h)-nafto{1,2- b}piran)-2,5-diona, 2¡'', 3''-dihidro-espiro (imidazolidin-4,4''- (4''h)-nadto{1,2-b}tiopiran)-2,5 dionma, 1'',2'', 3'', 4''- tetrahidro-espiro (imidazolidin-4, 1''-benzo {a}antracen)-2,5- diona, 2'', 3'' -dihidro-espiro (imidazolidin-4,1''-fenalen)-2,5- diona, 1'', 2'', 3'', 4''-tetrahidro-espiro (imidazolidin- 4,1''fenalen)-2, 5-diona, 1'',2`''3'',4''-tetrahidro- espiro(imidazolidin-4,1''-fenantren)¿2,5-diona, los isomeros 2,1 de los 2'',3''¡-dihidro-4''h-piran y 2'', 3'' -dihidro-4''h- tiopitran-derivados, los 2'',3'' -dihidro-4'' h-antra-cenopiran-y 2'',3''0-dihidro-4''h-antracenotiopiran-derivados, del isomero epiro- ,4'' del tetrahidrofenantren-derivado, el isomero {b} del benzantracen-derivado y los 2'', 3'' -diidro-4'' H- naftopiran.-, 2'', 3''-dihjidro-4''hnaftotiopiran y tetrahidrofenantren-derivados constituidos o disustituidos.
ES486007A 1978-11-16 1979-11-15 Un procedimiento de preparacion de un derivado de espiro- policicloimidazolidindiona Expired ES486007A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/961,335 US4181728A (en) 1978-11-16 1978-11-16 Spiro-polycyclicimidazolidinedione derivatives

Publications (1)

Publication Number Publication Date
ES486007A1 true ES486007A1 (es) 1980-09-01

Family

ID=25504341

Family Applications (1)

Application Number Title Priority Date Filing Date
ES486007A Expired ES486007A1 (es) 1978-11-16 1979-11-15 Un procedimiento de preparacion de un derivado de espiro- policicloimidazolidindiona

Country Status (23)

Country Link
US (1) US4181728A (es)
JP (2) JPS6052157B2 (es)
AR (1) AR222052A1 (es)
AT (1) AT369742B (es)
AU (1) AU515301B2 (es)
BE (1) BE880065A (es)
CA (1) CA1125294A (es)
CH (1) CH642358A5 (es)
DE (1) DE2946037A1 (es)
DK (1) DK484479A (es)
ES (1) ES486007A1 (es)
FI (1) FI66385C (es)
FR (1) FR2441627A1 (es)
GB (1) GB2038315B (es)
IE (1) IE49116B1 (es)
IL (1) IL58730A (es)
IT (1) IT1127231B (es)
LU (1) LU81890A1 (es)
NL (1) NL177689C (es)
PH (1) PH15672A (es)
PT (1) PT70452A (es)
SE (1) SE447731B (es)
YU (1) YU41678B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
ATE10940T1 (de) * 1981-05-12 1985-01-15 Imperial Chemical Industries Plc Pyrrolderivate.
US4464385A (en) * 1982-04-15 1984-08-07 Alcon Laboratories, Inc. Treatment of diabetic complications with hydantoins
US4540700A (en) * 1982-04-15 1985-09-10 Alcon Laboratories, Inc. Treatment of diabetic complications with certain spiro-imidazolidine-diones
JPS59500618A (ja) * 1982-04-15 1984-04-12 アルコン・ラボラトリ−ズ・インコ−ポレ−テッド スピロ―フルオロフルオレン化合物、その製造法およびアルド―スレダクターゼ活性を阻害する組成物
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
IL68314A0 (en) * 1982-04-15 1983-07-31 Alcon Lab Inc Method and composition for inhibiting aldose reductase activity and process for preparing spirofluorofluoren and spiro-difluorofluoren compounds
DE3342933A1 (de) * 1983-11-26 1985-06-05 Horst G. 5190 Stolberg Schumann Regalfoerderzeug
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4717725A (en) * 1984-04-11 1988-01-05 Alcon Laboratories, Inc. Ophthalmic wound healing with aldose reductase inhibitors
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4576143A (en) * 1984-10-05 1986-03-18 Clark Iii William T Method of immune modification by means of extracorporeal irradiation of the blood
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US5340829A (en) * 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
JPS6372140U (es) * 1986-10-29 1988-05-14
JPS63119451U (es) * 1987-01-30 1988-08-02
WO1992000071A1 (en) * 1989-02-10 1992-01-09 Washington Research Foundation Immunoregulatory agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
DE1032257B (de) * 1954-05-27 1958-06-19 Cutter Lab Verfahren zur Herstellung neuer Hydantoine
GB796069A (en) * 1955-12-23 1958-06-04 Ici Ltd Substituted hydantoins
GB818724A (en) * 1956-10-18 1959-08-19 Ici Ltd Hydantoin derivatives
US3532744A (en) * 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4078064A (en) * 1976-08-18 1978-03-07 E. R. Squibb & Sons, Inc. 8H-Pyrazolo[4',3':5,6]pyrido[3,4-e][1,2,4]triazolo[1,5-a]pyrimidines
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4127665A (en) * 1978-01-18 1978-11-28 Pfizer Inc. Thienohydantoin derivatives

Also Published As

Publication number Publication date
LU81890A1 (fr) 1980-06-05
GB2038315B (en) 1982-08-11
IT1127231B (it) 1986-05-21
GB2038315A (en) 1980-07-23
FI66385C (fi) 1984-10-10
FR2441627B1 (es) 1983-06-03
NL7908352A (nl) 1980-05-20
AR222052A1 (es) 1981-04-15
FR2441627A1 (fr) 1980-06-13
IT7927311A0 (it) 1979-11-15
AU5288079A (en) 1980-05-22
IE49116B1 (en) 1985-08-07
JPS5589268A (en) 1980-07-05
FI66385B (fi) 1984-06-29
CA1125294A (en) 1982-06-08
PH15672A (en) 1983-03-11
NL177689B (nl) 1985-06-03
JPS60120870A (ja) 1985-06-28
ATA729779A (de) 1982-06-15
IE792184L (en) 1980-05-16
SE447731B (sv) 1986-12-08
US4181728A (en) 1980-01-01
DK484479A (da) 1980-05-17
SE7909439L (sv) 1980-05-17
DE2946037A1 (de) 1980-05-22
IL58730A0 (en) 1980-02-29
IL58730A (en) 1984-01-31
AU515301B2 (en) 1981-03-26
AT369742B (de) 1983-01-25
CH642358A5 (fr) 1984-04-13
NL177689C (nl) 1985-11-01
YU41678B (en) 1987-12-31
FI793586A (fi) 1980-05-17
JPS6052157B2 (ja) 1985-11-18
PT70452A (en) 1979-12-01
BE880065A (fr) 1980-05-16
JPS6144868B2 (es) 1986-10-04
YU277379A (en) 1983-01-21

Similar Documents

Publication Publication Date Title
ES486007A1 (es) Un procedimiento de preparacion de un derivado de espiro- policicloimidazolidindiona
IE790088L (en) Thienohydantoin derivatives
GB2061726B (en) Furocoumarin for the photochemotherapy of psoriasis
IE810261L (en) Spirohydantoins
AU526160B2 (en) Milbemycin compounds as anthelmintic agents
JPS57108092A (en) 7-oxo-4-thia-1-aza(3,2,0)heptane and 7-oxo-4-thia-1-aza(3,2,0)hept-2-ene derivative
IE791592L (en) Spiro-oxazole derivatives
IN170909B (es)
IE800571L (en) Spiro-imidazolidine.
AU2292088A (en) Cathartics
IE791540L (en) Spiro-furanohydantoin derivatives
IE801280L (en) Sugar esters and glycosides
AU523484B2 (en) 5-methoxypsoralen treatment for psoriasis
EP0157623A3 (en) Optically active isomers of benzopyran derivatives useful for treating cardiovascular disease
AU6642281A (en) Isolation of plasminogen activators useful as therapeutic anddiagnostic agents
CA1262912C (en) TETRAHYDROFURANYLIC SUBSTITUTION DERIVATIVES OF PROSTAGLANDIN ANALOGS
DE3068652D1 (en) 6-keto pge1 compounds, their preparation and therapeutic application, pgi1 compounds
IE800672L (en) Spiro-quinolone hydantoins
IE810965L (en) Synthesis of 3, 8-dioxabicyclo £3, 2, 1| octanes
AU537117B2 (en) Alpha-cyano-4-fluoro-3-phenoxybenzyl ester
HUT44792A (en) Process for production of 13 alpha-alkyl-gonane-delta 9,/11/-5,10 epoxid derivatives
IE42994L (en) 1,3-dihydrospiro [isobenzofuran-1,4'-piperidine]s
SU643331A1 (ru) Устройство дл групповой обработки древесины
AU530964B2 (en) Composition for treatment of eczema
AU542627B2 (en) Total synthesis of 1rs, 5rs, -4-(4,8-dimethyl-5-hydroxy- 7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo(3.2.1) octane- 1-acetic acid

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970203